Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 5/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22064475 | 0.96 | KMT2A (0.42) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL13474845 | 0.94 | KMT2A (0.43) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL7481837 | 0.94 | KMT2A (0.46) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL13386836 | 0.93 | KMT2A (0.44) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL13474889 | 0.92 | KMT2A (0.40) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL19937331 | 0.91 | GAA (0.45) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL13474887 | 0.91 | KMT2A (0.44) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL27957816 | 0.91 | KMT2A (0.44) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL19884576 | 0.90 | KMT2A (0.39) | KMT2AGAAMEN1TSHRCYP2D6 | |
| SCHEMBL16866169 | 0.90 | FAAH (0.40) | KMT2AGAAMEN1TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312908-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-3303518-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-06-10 | — | — | EP | disclosed |
| US-10465117-B2 | Liquid-crystalline medium, method for the stabilization thereof, and liquid-crystal display | MERCK PATENT GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-20180163134-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| US-20180163136-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| US-20180163134-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| US-20180163136-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| EP-3327102-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2018-05-30 | — | — | EP | disclosed |
| EP-3327103-A1 | LIQUID CRYSTAL MEDIUM, METHOD FOR THE STABILISATION THEREOF AND LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2018-05-30 | — | — | EP | disclosed |
| US-9920248-B2 | Compounds and liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-20140111730-A1 | Liquid-crystalline medium, method for the stabilization thereof, and liquid-crystal display | MERCK PATENT GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2722381-A2 | Liquid crystal medium, method for the stabilisation thereof and liquid crystal display | Merck Patent GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-20120268706-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120268706-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-0309402-B2 | N-substituted hindered amine stabilizers | CIBA SC HOLDING AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| EP-0309402-B1 | N-substituted hindered amine stabilizers | CIBA GEIGY AG (CH) | 1995-01-11 | — | — | EP | disclosed |
| US-5204473-A | O-substituted N-hydroxy hindered amine stabilizers | CIBA-GEIGY CORPORATION (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0467844-A2 | Prevention of oxidation in petrochemical extraction solvents | CIBA-GEIGY AG (CH) | 1992-01-22 | — | — | EP | disclosed |
| US-4921962-A | REACTION OF AMINE WITH HYDROPEROXIDE | CIBA-GEIGY CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0309402-A1 | N-substituted hindered amine stabilizers | CIBA-GEIGY AG (CH) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120268706-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | NEFM, VIM, FLNB | KMT2A 4273/4885GAA 4098/4885MEN1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.